StockData
Erasca, Inc. logo

Erasca, Inc. (ERAS) stock

ERASNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$13.89−1.22 (-8.07%)

Close on Nov 17, 2026Market cap $4.86BP/E –Yield 0.00%

Erasca cash

Cash and short-term investments held at the end of each period.

Erasca's cash was $384.30M at Jun 30, 2026. For fiscal 2025 it was $341.80M, up 14.6% from the year before. The highest annual figure on record is $435.60M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$341.80M+14.6%
FY2024Dec 31, 2024$298.30M-4.5%
FY2023Dec 31, 2023$312.40M-28.3%
FY2022Dec 31, 2022$435.60M+5.1%
FY2021Dec 31, 2021$414.50M+249.2%
FY2020Dec 31, 2020$118.70M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$384.30M-0.6%
Q1 FY2026Mar 31, 2026$408.50M+34.1%
Q4 FY2025Dec 31, 2025$341.80M+14.6%
Q3 FY2025Sep 30, 2025$362.40M+13.6%
Q2 FY2025Jun 30, 2025$386.70M-5.3%
Q1 FY2025Mar 31, 2025$304.60M+2.3%
Q4 FY2024Dec 31, 2024$298.30M-4.5%
Q3 FY2024Sep 30, 2024$318.90M+7.5%
Q2 FY2024Jun 30, 2024$408.40M+28.8%
Q1 FY2024Mar 31, 2024$297.70M-23.6%
Q4 FY2023Dec 31, 2023$312.40M-28.3%
Q3 FY2023Sep 30, 2023$296.70M-16.6%
Q2 FY2023Jun 30, 2023$317.20M-14.6%
Q1 FY2023Mar 31, 2023$389.70M-0.7%
Q4 FY2022Dec 31, 2022$435.60M+5.1%
Q3 FY2022Sep 30, 2022$355.90M-26.9%
Q2 FY2022Jun 30, 2022$371.50M+91.8%
Q1 FY2022Mar 31, 2022$392.50M+130.9%
Q4 FY2021Dec 31, 2021$414.50M+249.2%
Q3 FY2021Sep 30, 2021$486.60M+684.6%
Q2 FY2021Jun 30, 2021$193.70M+85.6%
Q1 FY2021Mar 31, 2021$169.99M–
Q4 FY2020Dec 31, 2020$118.70M–
Q3 FY2020Sep 30, 2020$62.02M–
Q2 FY2020Jun 30, 2020$104.34M–

More Erasca figures

See a number that looks wrong?